Skip to main content

Drug Interactions between hydrocortisone / lidocaine / psyllium topical and ibutilide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

lidocaine topical ibutilide

Applies to: hydrocortisone / lidocaine / psyllium topical and ibutilide

Coadministration of topical lidocaine with class III antiarrhythmics (e.g., amiodarone, dofetilide, sotalol) may lead to additive cardiovascular effects. Drug interaction studies evaluating class III antiarrhythmics with topical lidocaine formulations are unavailable. The degree of systemic absorption of topical lidocaine may be dependent on the duration of application and the applied surface area. Some authorities recommend increased clinical monitoring during concomitant use.

References (2)
  1. (2023) "Product Information. LMX 4 (lidocaine topical)." Ferndale Pharmaceuticals Ltd
  2. (2024) "Product Information. Xylocaine Topical (lidocaine topical)." Aspen Pharmacare Australia Pty Ltd

Drug and food interactions

Moderate

psyllium food

Applies to: hydrocortisone / lidocaine / psyllium topical

ADJUST DOSING INTERVAL: Bulk-forming laxatives such as guar gum, psyllium, polycarbophil, or methylcellulose may affect the bioavailability of concomitantly administered substances due to their effect on the rate of gastrointestinal transit and gastric emptying.

MANAGEMENT: In general, oral medications should be administered at least 2 hours before or 2 hours after dosing of the bulk-forming laxative.

References (1)
  1. (2001) "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.